⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3545819 | 0.87 | — | — | |
| SCHEMBL6104479 | 0.85 | LMNA (0.52) | — | |
| SCHEMBL7261781 | 0.83 | TSHR (0.55) | — | |
| SCHEMBL2722289 | 0.83 | TSHR (0.55) | — | |
| SCHEMBL95982 | 0.81 | TSHR (1.00) | — | |
| SCHEMBL10064430 | 0.80 | — | — | |
| SCHEMBL20254092 | 0.79 | TSHR (0.42) | — | |
| Acetic Acid SCHEMBL6932730 | 0.79 | TSHR (0.81) | — | |
| SCHEMBL342851 | 0.79 | — | — | |
| SCHEMBL14042508 | 0.78 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 246 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4138923-A1 | DRUG ANTIBODY CONJUGATES | Pharma Mar, S.A. (ES) | 2023-03-01 | — | — | EP | claimed |
| US-20230012681-A1 | ANTIBODY DRUG CONJUGATES COMPRISING ECTEINASCIDIN DERIVATIVES | PHARMA MAR, S.A. (ES) | 2023-01-19 | — | — | US | claimed |
| CN-114615999-A | Drug antibody conjugates | 法马马有限公司 | 2022-06-10 | — | — | CN | claimed |
| WO-2021214126-A1 | DRUG ANTIBODY CONJUGATES | PHARMA MAR, S.A. (ES) | 2021-10-28 | — | — | WO | claimed |
| EP-3003386-A1 | ANTIBODY DRUG CONJUGATES | Pharma Mar S.A. (ES) | 2016-04-13 | — | — | EP | claimed |
| WO-2014191578-A1 | ANTIBODY DRUG CONJUGATES | PHARMA MAR, S.A. (ES) | 2014-12-04 | — | — | WO | claimed |
| US-12410148-B2 | Antibody drug conjugates | PARMA MAR, S.A. (ES) | 2025-09-09 | — | — | US | disclosed |
| WO-2025032041-A1 | ORGANOMETALLIC CLUSTER CONTAINING SULFUR FOR EUV LITHOGRAPHY BACKGROUND | MERCK PATENT GMBH (DE) | 2025-02-13 | — | — | WO | disclosed |
| US-20250007192-A1 | METHODS FOR THE ACYLATION OF MAYTANSINOL | IMMUNOGEN, INC. | 2025-01-02 | — | — | US | disclosed |
| US-20240313444-A1 | METHODS FOR THE ACYLATION OF MAYTANSINOL | IMMUNOGEN INC (US) | 2024-09-19 | — | — | US | disclosed |
| US-20240145953-A1 | METHODS FOR THE ACYLATION OF MAYTANSINOL | IMMUNOGEN INC (US) | 2024-05-02 | — | — | US | disclosed |
| US-20240131180-A1 | DRUG ANTIBODY CONJUGATES | PHARMA MAR, S.A. (ES) | 2024-04-25 | — | — | US | disclosed |
| EP-4025253-B1 | DRUG ANTIBODY CONJUGATES | PHARMA MAR SA (ES) | 2024-03-20 | — | — | EP | disclosed |
| WO-2001024763-A2 | COMPOSITIONS AND METHODS FOR TREATING CANCER USING IMMUNOCONJUGATES AND CHEMOTHERAPEUTIC AGENTS | IMMUNOGEN, INC. (US) | 2001-04-12 | — | — | WO | disclosed |
| EP-1000039-A1 | SUBSTITUTED QUINAZOLINE DERIVATIVES AND THEIR USE AS TYROSINE KINASE INHIBITORS | American Cyanamid Company (US) | 2000-05-17 | — | — | EP | disclosed |
| WO-1999009016-A1 | SUBSTITUTED QUINAZOLINE DERIVATIVES AND THEIR USE AS TYROSINE KINASE INHIBITORS | AMERICAN CYANAMID COMPANY (US) | 1999-02-25 | — | — | WO | disclosed |
| EP-0425235-B1 | Cytotoxic agents comprising maytansinoids and their therapeutic use | IMMUNOGEN INC (US) | 1996-09-25 | — | — | EP | disclosed |
| US-5416064-A | Antitumor agents | IMMUNOGEN, INC. (US) | 1995-05-16 | — | — | US | disclosed |
| US-5208020-A | Cytotoxic agents comprising maytansinoids and their therapeutic use | IMMUNOGEN INC. (US) | 1993-05-04 | — | — | US | disclosed |
| EP-0425235-A2 | Cytotoxic agents comprising maytansinoids and their therapeutic use | IMMUNOGEN INC (US) | 1991-05-02 | — | — | EP | disclosed |